在初级保健中优化多病共存和多重用药老年人的处方(OPTICA):整群随机临床试验
该整群随机临床试验在瑞士初级保健中评估以电子临床决策支持系统(eCDSS)为核心的药物审查干预对多病共存和多重用药老年人用药适当性和处方遗漏的影响。在43个全科医生集群中招募323例患者,12个月时用药适当性改善(OR 1.05,95%CI 0.59-1.87)和处方遗漏数(OR 0.90,95%CI 0.41-1.96)的意向性治疗分析结果均不确定。干预可安全实施,未对患者造成伤害。
要点
- 在43个全科医生集群中招募323例多病共存和多重用药的老年患者(中位年龄77岁,45%为女性)。
- 12个月时用药适当性改善的OR为1.05(95%CI 0.59-1.87),处方遗漏数的OR为0.90(95%CI 0.41-1.96),结果不确定。
- 12个月随访时安全性结局未见明确差异,但干预组在6个月和12个月报告的安全性事件少于对照组。
核心结论
- 在这项全科医生和老年人的随机试验中,与按常规护理讨论药物相比,以eCDSS为核心的药物审查干预是否在12个月时改善用药适当性或减少处方遗漏,结果不确定。
- 该干预可安全实施,未对患者造成任何伤害。
研究设计与样本
- 整群随机临床试验,在瑞士初级保健中于2018年12月至2021年2月期间开展。
- 纳入标准为年龄≥65岁、患有三种或以上慢性病并服用五种或以上长期药物的患者。
- 共43个全科医生集群、323例患者被招募(中位年龄77岁,四分位距73-83岁;45%(n=146)为女性)。
- 干预组为21名全科医生和160例患者,对照组为22名全科医生和163例患者。
- 干预措施为全科医生实施以eCDSS为核心的优化药物治疗,随后进行全科医生与患者的共享决策;对照为患者与全科医生按常规护理讨论药物。
主要发现
- 平均每例患者报告实施了一项停药或 start 药物的建议。
- 12个月时,意向性治疗分析中用药适当性改善的OR为1.05(95%CI 0.59-1.87),处方遗漏数的OR为0.90(95%CI 0.41-1.96),结果不确定。
- 符合方案分析结果同样不确定。
- 12个月随访时安全性结局未见明确差异证据,但干预组在6个月和12个月报告的安全性事件少于对照组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the effects of a primary care medication review intervention centred around an electronic clinical decision support system (eCDSS) on appropriateness of medication and the number of prescribing omissions in older adults with multimorbidity and polypharmacy compared with a discussion about medication in line with usual care. DESIGN: Cluster randomised clinical trial. SETTING: Swiss primary care, between December 2018 and February 2021. PARTICIPANTS: Eligible patients were ≥65 years of age with three or more chronic conditions and five or more long term medications. INTERVENTION: The intervention to optimise pharmacotherapy centred around an eCDSS was conducted by general practitioners, followed by shared decision making between general practitioners and patients, and was compared with a discussion about medication in line with usual care between patients and general practitioners. MAIN OUTCOME MEASURES: Primary outcomes were improvement in the Medication Appropriateness Index (MAI) and the Assessment of Underutilisation (AOU) at 12 months. Secondary outcomes included number of medications, falls, fractures, and quality of life. RESULTS: In 43 general practitioner clusters, 323 patients were recruited (median age 77 (interquartile range 73-83) years; 45% (n=146) women). Twenty one general practitioners with 160 patients were assigned to the intervention group and 22 general practitioners with 163 patients to the control group. On average, one recommendation to stop or start a medication was reported to be implemented per patient. At 12 months, the results of the intention-to-treat analysis of the improvement in appropriateness of medication (odds ratio 1.05, 95% confidence interval 0.59 to 1.87) and the number of prescribing omissions (0.90, 0.41 to 1.96) were inconclusive. The same was the case for the per protocol analysis. No clear evidence was found for a difference in safety outcomes at the 12 month follow-up, but fewer safety events were reported in the intervention group than in the control group at six and 12 months. CONCLUSIONS: In this randomised trial of general practitioners and older adults, the results were inconclusive as to whether the medication review intervention centred around the use of an eCDSS led to an improvement in appropriateness of medication or a reduction in prescribing omissions at 12 months compared with a discussion about medication in line with usual care. Nevertheless, the intervention could be safely delivered without causing any harm to patients. TRIAL REGISTRATION: NCT03724539Clinicaltrials.gov NCT03724539.
引用
- Jungo KT, Ansorg AK, Floriani C, et al. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. BMJ. 2023. PMID: 37225248. doi:10.1136/bmj-2022-074054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。